Pillai et al., by evaluating a large series of individuals with type 2 diabetes, of whom 1822 were treated with basal insulin peglispro and 1270 with insulin glargine, found that those with the PNPLA3 (148M/M) genotype treated with basal insulin peglispro were more prone to developing an increased intrahepatic fat content assessed with Magnetic Resonance Imaging [91]. Here, INS is linked to type 2 diabetes mellitus.